Dr. Sunny Wang
Claim this profileVeterans Affairs Medical Center - San Francisco
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
16 drugs studied
Area of expertise
1Lung Cancer
Stage II
Stage I
Stage III
2Non-Small Cell Lung Cancer
Stage II
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Sunny Wang is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
More about Sunny Wang
Clinical Trial Related11 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Sunny Wang has experience with
- Pembrolizumab
- Carboplatin
- Sotorasib
- Biospecimen Collection
- N-803 (ALT-803)
- Crizotinib
Breakdown of trials Sunny Wang has run
Lung Cancer
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Lung Carcinoma
Anaplastic Large Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sunny Wang specialize in?
Sunny Wang focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage I.
Is Sunny Wang currently recruiting for clinical trials?
Yes, Sunny Wang is currently recruiting for 4 clinical trials in San Francisco California. If you're interested in participating, you should apply.
Are there any treatments that Sunny Wang has studied deeply?
Yes, Sunny Wang has studied treatments such as Pembrolizumab, Carboplatin, Sotorasib.
What is the best way to schedule an appointment with Sunny Wang?
Apply for one of the trials that Sunny Wang is conducting.
What is the office address of Sunny Wang?
The office of Sunny Wang is located at: Veterans Affairs Medical Center - San Francisco, San Francisco, California 94121 United States. This is the address for their practice at the Veterans Affairs Medical Center - San Francisco.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.